Pear Therapeutics to Participate in Evercore ISI HEALTHCONx Conference
BOSTON--(BUSINESS WIRE)--Nov 20, 2018--Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will participate in a digital therapeutics panel discussion at the Evercore ISI HEALTHCONx Conference on Wednesday, November 28 at 6:00 p.m. at the Boston Harbor Hotel.
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia, and multiple sclerosis. Our lead product, reSET ®, treats Substance Use Disorder (SUD) and was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O™, for the treatment of Opioid Use Disorder (OUD), is currently under FDA review with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005019/en/
CONTACT: Media and Investors:
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL FDA
SOURCE: Pear Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 11/20/2018 07:00 AM/DISC: 11/20/2018 07:01 AM